Skip to main content

Security report for ompharmaservices.com

Owen Mumford Pharmaceutical Services · Healthcare · United Kingdom

Medium risk. 4 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

67/100

Risk levelMedium

0–100, higher is better. How it is calculated

Owen Mumford Pharmaceutical Services is a UK-based company specializing in the development and manufacture of innovative drug delivery medical devices, including auto-injectors and safety syringes. The company targets pharmaceutical partners and healthcare providers, offering both platform products and bespoke solutions. Their market position is that of an established mid-sized player with a focus on quality and regulatory compliance, supported by a professional and content-rich website. Technically, the website is built on WordPress with modern SEO and analytics tools, delivering a good user experience with mobile optimization and clear navigation. Security posture is solid with HTTPS and cookie consent mechanisms, though the absence of WHOIS data and security headers suggests room for improvement. Overall, the site is trustworthy and safe, with no adult or questionable content detected. However, the lack of WHOIS registration data reduces domain trustworthiness and should be investigated further.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

4 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…
  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching ompharmaservices.com

This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
77
Security headers
30
Email security
60
DNS health
65
Network security
100
GDPR outside view
68
Average
67

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention ompharmaservices.com, from OffSeq Breach.

No leaked records found

Breach holds no records for ompharmaservices.com right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company operates in the healthcare sector, focusing on pharmaceutical device manufacturing and services. Their business model is B2B, serving pharmaceutical companies with drug delivery solutions. The website indicates a medium-sized enterprise founded in 2017, with a parent company Owen Mumford Ltd. The firm leverages partnerships and maintains a professional digital presence with clear product offerings and regulatory information. Their marketing and analytics ecosystem includes Microsoft Clarity, Google Tag Manager, and LinkedIn Insight Tag, supporting moderate user tracking and advertising transparency. The company demonstrates a consistent brand and content strategy, reinforcing its credibility in the healthcare manufacturing niche.

Security posture

The website enforces HTTPS and implements cookie consent, reflecting good baseline security and privacy practices. However, no explicit security headers (such as Content Security Policy or HSTS) were detected, which could enhance protection against common web attacks. The absence of publicly available security policies or incident response contacts limits transparency in security governance. No vulnerabilities or exposed sensitive data were found in the HTML content. The WHOIS data absence is a concern for domain legitimacy and could indicate privacy protection or registration issues. Overall, the security posture is good but could be strengthened with additional headers and published policies.

Recommendations

  1. Implement and verify HTTP security headers including CSP, HSTS, X-Frame-Options, and X-XSS-Protection to enhance web security.
  2. Publish a dedicated security policy and incident response contact information to improve transparency and trust.
  3. Investigate and resolve the missing WHOIS registration data to ensure domain legitimacy and reduce suspicion.
  4. Regularly audit third-party scripts and tracking tools to minimize potential vulnerabilities and privacy risks.
  5. Enhance accessibility features to improve compliance and user experience for all visitors.

Contact details published on the site

Addresses
Legal name
Owen Mumford Ltd
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Owen Mumford Pharmaceutical Services
Description
Proven experience developing innovative medical devices for drug delivery, extending from platform products to bespoke services.
Key services
Drug delivery device development, Manufacture of auto-injectors and safety syringes, Custom drug delivery solutions, Quality and regulatory support
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Yoast SEO plugin, jQuery, Google Tag Manager, Microsoft Clarity, LinkedIn Insight Tag
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Microsoft Clarity, Google Analytics (via GTM), LinkedIn Insight Tag
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Microsoft Clarity, LinkedIn Insight Tag, Google Analytics (via GTM)
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenge.
  2. Professional healthcare/pharmaceutical services site with clear product offerings.
  3. No WHOIS registration data found, which is unusual and warrants further investigation.
  4. Good privacy and cookie policy presence with consent mechanisms.
  5. No explicit security policies or incident response info publicly available.
  6. Uses modern tracking and analytics tools with moderate user tracking.
  7. No adult or questionable content detected; content is safe for general audiences.
Technical notes

Notes

The website is built on WordPress CMS with Yoast SEO plugin, jQuery, and modern analytics tools such as Microsoft Clarity and Google Tag Manager. The site loads with moderate performance and is mobile optimized with responsive design. SEO is well implemented with proper meta tags, Open Graph, and JSON-LD structured data describing the organization and products. No major technical debt or errors were detected in the HTML content. However, the site lacks explicit security headers and detailed hosting provider information. The use of multiple external domains for scripts and analytics is standard but requires ongoing monitoring for security and privacy compliance.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ompharmaservices.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ompharmaservices.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.